tradingkey.logo

Scinai Immunotherapeutics Ltd

SCNI
View Detailed Chart
0.832USD
-0.017-2.01%
Close 02/06, 16:00ETQuotes delayed by 15 min
1.26MMarket Cap
0.07P/E TTM

Scinai Immunotherapeutics Ltd

0.832
-0.017-2.01%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.01%

5 Days

-15.13%

1 Month

+0.62%

6 Months

-48.02%

Year to Date

+16.80%

1 Year

-78.81%

View Detailed Chart

Key Insights

Scinai Immunotherapeutics Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 231 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Scinai Immunotherapeutics Ltd's Score

Industry at a Glance

Industry Ranking
231 / 392
Overall Ranking
491 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Scinai Immunotherapeutics Ltd Highlights

StrengthsRisks
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Growing
The company is in a growing phase, with the latest annual income totaling USD 658.00K.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 0.07, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 166.27K shares, increasing 32.35% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.81.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Scinai Immunotherapeutics Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Scinai Immunotherapeutics Ltd Info

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Ticker SymbolSCNI
CompanyScinai Immunotherapeutics Ltd
CEOReichman (Amir)
Websitehttps://www.scinai.com/
KeyAI